Parnax Lab Limited

BSE: PARNAXLAB506128ISIN INE383L01019

Healthcare
Pharmaceuticals

Share price

₹101.05-2.95 (-2.84%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹182.00
52W low: ₹92.80
Off 52W high: -44.48%
1M return: -12.13%
3M return: -23.74%
6M return: -37.89%
1Y return: -22.12%
20D avg volume: 904
50 DMA: ₹118.47
200 DMA: ₹131.32

Key ratios Consolidated

Market cap: ₹116.06 Cr
Current price: ₹101.05
52W high / low: ₹182.00 / ₹92.80
Face value: ₹10.00
P/E: 12.97
P/B: 1.22
EPS (TTM): ₹7.79
Book value / share: ₹82.83
ROE: —
ROCE: 16.40%
Operating margin: —
Net margin: —
Debt / equity: 0.78
Net debt: ₹74.19 Cr
Interest cover: 3.79
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 61.3 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24
Income statement
	56.80	69.63	62.94	62.60	53.38	49.04	40.22	48.36	50.12	—
	0.15	1.99	0.97	0.63	0.18	0.43	0.19	0.95	0.11	—
	56.96	71.62	63.91	63.23	53.56	49.46	40.41	49.31	50.23	—
	56.36	68.39	59.52	58.03	49.10	45.51	38.96	44.44	44.83	—
	33.44	43.76	37.86	34.82	32.27	25.74	23.29	21.52	23.31	—
	0.11	0.00	0.04	0.00	0.33	0.39	0.07	0.14	0.37	—
	7.82	7.20	7.10	6.44	6.39	6.22	5.67	6.12	6.42	—
	1.64	1.61	1.47	1.40	1.22	1.28	1.23	1.39	1.50	—
	2.23	2.04	1.96	2.10	1.94	1.83	1.78	1.94	1.83	—
	12.37	14.09	11.66	11.76	9.57	9.91	8.71	10.34	11.58	—
	0.60	3.23	4.39	5.21	4.46	3.95	1.45	4.87	5.40	—
	0.00	-0.23	-1.14	0.00	0.00	0.00	0.00	0.00	0.00	—
	0.60	3.00	3.25	5.21	4.46	3.95	1.45	4.87	5.40	—
	0.17	0.81	0.53	1.58	1.18	1.03	0.23	1.46	1.42	—
	0.42	2.18	2.72	3.62	3.27	2.93	1.21	3.41	3.99	—
	0.37	1.90	2.37	3.15	2.85	2.55	1.06	2.97	3.47	—
Key metrics
	4.47	6.65	6.68	8.71	7.62	7.06	4.46	8.20	8.73	—
	7.90%	9.60%	10.60%	13.90%	14.30%	14.40%	11.10%	17.00%	17.40%	—
	0.70%	3.10%	4.30%	5.80%	6.10%	6.00%	3.00%	7.10%	8.00%	—
	—	3.50%	—	5.40%	—	4.50%	—	—	—	—
	6.40%	42.00%	56.50%	29.40%	6.50%	—	—	—	—	—
	-87.20%	-25.60%	124.80%	6.20%	-18.00%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	251.97	248.54	187.74	—
	3.74	3.78	1.68	—
	255.72	252.33	189.41	—
	242.30	235.05	173.74	—
	149.88	148.74	93.85	—
	0.15	0.34	0.46	—
	28.56	27.13	24.43	—
	6.12	5.71	5.39	—
	8.33	8.05	7.38	—
	49.88	47.07	40.54	—
	13.43	17.28	15.67	—
	-1.37	-1.37	0.00	—
	12.06	15.91	15.67	—
	3.09	4.11	4.13	—
	8.94	11.80	11.54	—
	7.79	10.27	10.05	—
Key metrics
	26.51	29.67	28.44	—
	10.52%	11.90%	15.10%	—
	3.55%	4.70%	6.10%	—
	—	16.40%	18.20%	—
	31.92%	32.40%	—	—
	-17.38%	2.30%	—	—
	—	-9.31	13.72	—
	—	0.68	2.80	—
	—	0.78	0.73	—
	—	74.19	60.09	—
	—	61.3	68.4	—
Balance sheet
	—	227.63	189.82	—
	—	90.69	64.78	—
	—	0.34	0.55	—
	—	37.81	30.76	—
	—	36.22	25.77	—
	—	14.04	5.15	—
	—	114.05	108.64	—
	—	32.25	21.35	—
	—	95.85	74.33	—
	—	74.53	60.64	—
	—	52.80	42.65	—
	—	21.73	17.99	—
	—	95.30	83.24	—
Cash flow
	—	8.00	32.30	—
	—	-16.39	-16.39	—
	—	8.18	-15.82	—
	—	17.31	18.58	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24
Income statement
	2.56	0.25	2.71	1.70	1.97	0.84	0.99	1.54	3.66	—
	0.21	1.76	0.22	0.20	0.19	0.19	0.17	0.18	0.17	—
	2.78	2.01	2.93	1.90	2.15	1.03	1.15	1.72	3.83	—
	1.93	3.28	1.96	1.24	1.84	1.14	0.95	1.35	2.43	—
	0.58	0.18	0.51	0.46	0.17	0.00	0.37	0.51	0.22	—
	0.24	0.00	0.26	0.24	0.96	0.90	0.07	0.18	1.11	—
	0.21	0.23	0.28	0.23	0.21	0.22	0.25	0.22	0.21	—
	0.00	0.01	0.00	0.02	0.01	0.01	0.01	0.00	0.01	—
	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	—
	0.77	2.92	0.68	0.38	0.25	0.35	0.23	0.43	0.87	—
	0.84	-1.27	0.97	0.66	0.31	-0.11	0.21	0.36	1.40	—
	0.00	-0.01	-0.02	0.00	0.00	0.00	—	—	—	—
	0.84	-1.28	0.95	0.66	0.31	-0.11	0.21	0.36	1.40	—
	0.00	-0.73	0.24	0.17	0.08	0.03	0.05	0.09	0.35	—
	0.85	-0.55	0.71	0.49	0.23	-0.08	0.16	0.27	1.05	—
	0.74	-0.48	0.62	0.43	0.20	-0.07	0.14	0.24	0.91	—
Key metrics
	0.86	-1.25	0.97	0.70	0.34	-0.08	0.24	0.38	1.43	—
	33.60%	-500.00%	35.80%	41.20%	17.30%	-9.50%	24.20%	24.70%	39.10%	—
	33.20%	-220.00%	26.20%	28.80%	11.70%	-9.50%	16.20%	17.50%	28.70%	—
	—	-5.40%	—	2.80%	—	-0.40%	—	—	—	—
	29.90%	-70.20%	173.70%	10.40%	-46.20%	—	—	—	—	—
	269.60%	-587.50%	343.70%	81.50%	-78.10%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	7.22	6.63	7.02	—
	2.39	2.37	0.71	—
	9.62	8.99	7.73	—
	8.41	8.31	5.87	—
	1.73	1.32	1.10	—
	0.74	1.46	1.77	—
	0.95	0.94	0.90	—
	0.03	0.03	0.02	—
	0.08	0.06	0.06	—
	4.75	4.23	1.88	—
	1.20	0.68	1.86	—
	-0.03	-0.04	0.00	—
	1.17	0.65	1.86	—
	-0.32	0.24	0.46	—
	1.50	0.89	1.40	—
	1.31	0.77	1.21	—
Key metrics
	1.28	0.74	1.94	—
	17.73%	11.20%	27.60%	—
	20.78%	13.40%	19.90%	—
	—	2.90%	8.20%	—
	35.21%	-5.60%	—	—
	158.62%	-36.40%	—	—
	—	-0.75	0.28	—
	—	-0.81	0.20	—
	—	0.01	0.02	—
	—	-0.16	-0.09	—
	—	42.9	14.6	—
Balance sheet
	—	24.60	24.72	—
	—	11.82	10.69	—
	—	0.32	0.50	—
	—	0.42	0.85	—
	—	0.80	0.78	—
	—	0.99	0.79	—
	—	0.39	0.43	—
	—	0.44	1.35	—
	—	1.00	1.74	—
	—	0.16	0.41	—
	—	0.00	0.00	—
	—	0.16	0.41	—
	—	23.42	22.54	—
Cash flow
	—	-0.72	0.28	—
	—	0.57	-0.19	—
	—	-0.03	-0.02	—
	—	0.03	0.00	—

Compounded growth

Standalone

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +35.21%
Profit YoY (TTM): +158.62%

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +31.92%
Profit YoY (TTM): -17.38%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 72.29%

Quarter	September 2026	June 2026
Promoter %	72.29%	72.29%

Holder	Type	Holding	Previous	Change
PRAKASH MAHASUKHLAL SHAH	Promoter	13.61%	10.46%	+3.15%
MIHIR PRAKASH SHAH	Promoter	13.22%	9.94%	+3.28%
BINOY BAIJU SHAH	Promoter	11.92%	11.92%	0.00%
PRAGNA PRAKASH SHAH	Promoter Group	9.28%	9.28%	0.00%
ILA B SHAH	Promoter Group	8.71%	11.86%	-3.15%
BAIJU MAHASUKHLAL SHAH	Promoter	8.29%	11.57%	-3.28%
AMI MIHIR SHAH	Promoter Group	7.26%	7.26%	0.00%
Suman Gupta	Public	1.62%	1.62%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Parnax Lab Limited	116	101.05	12.97	16.40%	+31.92% TTM	-17.38% TTM	-22.12%

Filings & corporate actions

Recent announcements

Parnax Lab Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2026 ,inter alia, to consider and approve Standalone and Consolidated Un-audited ....3 Nov 2026 · Board Meeting / Board Meeting
Please find enclosed herewith the confirmation certificate from RTA under Reg. 74 (5) of SEBI (DP) Regulations, 2018.14 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed herewith the Voting results of AGM held on 29.09.202630 Sep 2026 · AGM/EGM / AGM
Please find enclosed herewith the appointment of M/s Ladha Singhal & Associates, Chartered Accountants (Firm Registration No. 120241W) as the Statutory Auditors of the Company for a first ....29 Sep 2026 · Company Update / Appointment of Statutory Auditor/s
Please find enclosed herewith the AGM Proceedings held today i.e. September 29, 2026.29 Sep 2026 · AGM/EGM / AGM
Closure of Trading Window for the Quarter and Half Year Ended September, 202628 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Please find enclosed herewith the Newspaper Advertisement regarding AGM Notice for the year ended March 31, 2026.7 Sep 2026 · Company Update / Newspaper Publication
Please find enclosed herewith the Notice of the 44th AGM of the Company.7 Sep 2026 · AGM/EGM / AGM
Please find enclosed herewith the Annual Report for the year ended March 31, 2026.7 Sep 2026 · Others / Reg. 34 (1) Annual Report
Please find enclosed herewith the Notice of Book Closure for the purpose of 44th AGM of the Company to be held on 29th September, 2026.26 Aug 2026 · Corp. Action / Book Closure
Outcome of BM held today i.e. 26th August, 202626 Aug 2026 · Others / Outcome without intimation
Please find enclosed herewith the Financials Results for the Quarter and Three Months Ended June, 2026.14 Aug 2026 · Result / Financial Results
Please find enclosed herewith the outcome of BM w.r.t. the appointment of Statutory Auditor.14 Aug 2026 · Company Update / Appointment of Statutory Auditor/s
Board Meeting Outcome14 Aug 2026 · Board Meeting / Outcome of Board Meeting
The Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(1)(a)(ii)of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, ....14 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 10(7) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(1)(a)(ii)of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, ....14 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 10(7) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(1)(a)(ii)of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, ....14 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 10(7) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(1)(a)(ii)of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, ....14 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 10(7) of SEBI (SAST) Regulations, 2011
Please find enclosed herewith the scrutinizer report of Postal Ballot Results w.r.t. the re-appointment of Mr. Yogesh K. Varia, as an ID on the Board.10 Aug 2026 · AGM/EGM / Postal Ballot
Please find enclosed herewith the Reg. 30 w.r.t. the re-appointment of Mr. Yogesh K. Varia, as an ID w.e.f. 28th May, 2026, for a second term of 5 years.10 Aug 2026 · Company Update / Change in Management
Please find enclosed herewith the Postal Ballot Outcome w.r.t. the Re-appointment of Mr. Yogesh K. Varia as an ID for a second term of 5 years w.e.f. 28th May, 2026.10 Aug 2026 · AGM/EGM / Postal Ballot
Parnax Lab Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Standalone and Consolidated Un-audited ....5 Aug 2026 · Board Meeting / Board Meeting
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mihir Shah3 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Prakash Shah3 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mihir Shah, Baiju Shah, Prakash Shah, Ila B Shah23 Jul 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Baiju Shah23 Jul 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ila B Shah23 Jul 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mihir Shah22 Jul 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Prakash Mahasukhlal Shah22 Jul 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Please find enclosed herewith the Confirmation Certificate under Regulation 74(5) from RTA for the Quarter Ended June 30, 2026.13 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed herewith the Newspaper Publication regarding confirming dispatch of Postal Ballot Notice.9 Jul 2026 · Company Update / Newspaper Publication
Please find enclosed herewith the Postal Ballot Notice for seeking approval of Shareholders of the company w.r.t. the Re-appointment of Mr. Yogesh Kantilal Varia (DIN: 09186184) as a Non-Executive ....8 Jul 2026 · AGM/EGM / Postal Ballot
Please find enclosed herewith the Closure of Trading Window Intimation for the Quarter and Three Months Ended June, 2026.29 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, ....27 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Reg. 2011
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, ....27 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Reg. 2011
Please find enclosed herewith the Annual Secretarial Compliance Report under reg. 24(A) for the Year ended March, 2026.30 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
Please find enclosed herewith the Intimation regarding the Re-appointment of Mr. Yogesh K. Varia as an Independent Director of the Company, for a second term of 5 consecutive years w.e.f. ....28 May 2026 · Company Update / Change in Management
Please find enclosed herewith the Audited Results for the Quarter and Year Ended March, 2026, along with Auditor''s Report.28 May 2026 · Result / Financial Results
Board Meeting Outcome for Consideration and Approval of Standalone & Consolidated Audited Financial Results of the Company for the quarter and year ended 31st March, 2026, along with Auditor's ....28 May 2026 · Board Meeting / Outcome of Board Meeting
Parnax Lab Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 ,inter alia, to consider and approve Standalone and Consolidated Audited ....20 May 2026 · Board Meeting / Board Meeting

Board meetings

12 Nov 2026 Board Meeting - Financial Results
14 Aug 2026 Board Meeting - Financial Results